Ocean Biomedical OCEA
OTC OCEA
$0.00 +0.00 (+0.00%)
At close: Oct 20, 2026 · 4:00 PM EDT

Ocean Biomedical, Inc. (OCEA) Total Current Liabilities (2021 - 2025)

Updated

Ocean Biomedical (OCEA) posted Total Current Liabilities of $26.57 million for Q1 2025, down 11.8% from $30.11 million a year earlier and down 21.6% from the prior quarter.

Analysis

Ocean Biomedical, Inc. (OCEA) Total Current Liabilities (2021 - 2025) Analysis & Trends

At the end of FY2024, Ocean Biomedical's Total Current Liabilities came in at $33.89 million, up 12.9% from FY2023.

  • Annual Total Current Liabilities shows a three-year compound annual growth rate of 416.2% (FY2021 to FY2024).
  • In prior years, Ocean Biomedical's Total Current Liabilities was $30.01 million in FY2023 (+137.0%), $12.66 million in FY2022 and $246,444 in FY2021.
  • The Q1 2025 figure stands as the lowest quarterly Total Current Liabilities since Q1 2023.
  • On a year-over-year basis, Total Current Liabilities increased in five of the last six quarters, with growth averaging 28.6%.
  • According to Business Quant data, Total Current Liabilities for the three prior quarters was $33.89 million (Q4 2024), $31.83 million (Q3 2024) and $30.74 million (Q2 2024).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 26.57 Mn
Dec 31, 2024 33.89 Mn
Sep 30, 2024 31.83 Mn
Jun 30, 2024 30.74 Mn
Mar 31, 2024 30.11 Mn
Dec 31, 2023 30.01 Mn
Sep 30, 2023 30.85 Mn
Jun 30, 2023 29.79 Mn
Mar 31, 2023 23.75 Mn
Dec 31, 2022 12.66 Mn
Sep 30, 2022 2.09 Mn
Jun 30, 2022 506,026.00
Mar 31, 2022 102,167.00
Dec 31, 2021 246,444.00
API Access

Ocean Biomedical, Inc. Total Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=OCEA&period=max&api_key=YOUR_API_KEY